Glucose Monitoring Global Market

Glucose Monitoring Global Market – Forecast To 2027

Publishing Date :	May, 2021
Report Code :	HCMD0148
Price:	Single license $4,950 Site license $6,750 Global license $9,000

Note: The report would be dispatched after confirmation of payment

Glucose Monitoring consists of products that are essential for measuring glucose levels in diabetes patients. With the projected rise in the aged population and awareness about diabetes conditions, the market is focused on growing with newer technology and improved products. According to IQ4I analysis, the Glucose Monitoring global market is expected to grow at a low single digit CAGR from 2020 to 2027 reach $15,321.8 million by 2027.

Factors driving the Glucose Monitoring market are the global rise in the prevalence and incidence of diabetes, increasing demand for a less minimally invasive or non-invasive and point-of-care device; increasing R&D investments are driving the market growth, whereas, the growing diffusion of smart devices and digital platforms increasing compliance and management of diabetes is creating opportunities in the coming years. The high cost of the products, frequent product recalls and inadequate reimbursement is restraining the market growth. The stringent regulations, privacy concerns and safety issues are threats for the market growth.

Glucose Monitoring global market is classified based on products, sample type, end-users and geography. The product segment is divided into three segments i.e., Invasive, Non-Invasive and lab-based glucose monitoring products. The Invasive glucose monitoring products segment accounted for the largest share in 2020 due to technological advancements, easy use, and patient-friendly nature of products. Invasive products are further divided into Self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) products. The self glucose monitoring segment accounted for the largest share in 2020 due to their relatively lower cost. The Self glucose monitoring products are further classified into blood glucose monitors, blood glucose test strips, lancets and others. The blood glucose testing strips segment accounted for the largest share in 2020 due development of no coding strips. The continuous glucose monitoring market includes sensors/receivers and transmitters. The continuous glucose market includes products sensors/receivers and transmitters. The continuous glucose segment is the fastest-growing segment and is projected to grow at a high single digit CAGR from 2020 to 2027.

Based on sample type the market is segmented into blood, urine and others. The blood segment accounted for the largest share in 2020 and is projected to grow at a low single CAGR from 2020 to 2027 due to the accuracy of results. Other source-based glucose monitoring segment is the fastest-growing segment and is projected to grow at a double digit CAGR from 2020 to 2027 due to increased R&D investment, many products are CE approved and expected to launch very soon in the market.

Based on end-users the market is segmented into hospitals, private clinics, home care and ambulatory settings. Among end-users, the home care segment accounted for the largest share in 2020 and is projected to grow at low single digit CAGR from 2020 to 2027 due to the availability of over the counter (OTC) self blood glucose monitor and ease in operating these monitors and thereby reducing the frequent visits to hospitals or clinics for checking glucose levels.

Based on geography the market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of E.U.), Asia-Pacific (Japan, China, India and Rest of APAC) and the Rest of the World (Brazil, Middle East & others and Rest of Latin America). North America accounts for the highest market share in 2020 followed by Europe. The steep rise in the aging population, advancement in technology, awareness of people about treatment options and favorable government policies are driving factors of the glucose monitoring market. However, Asian countries especially India and China are the fastest-growing regions with their growing demand for glucose monitoring products.

Major players in the Glucose monitoring market include Abbott Laboratories (U.S.), Dexcom (U.S.), Roche (Switzerland), LifeScan (U.S.), Medtronic, Inc. (Ireland), PHC Holding (Ascensia) (Japan), Arkray (Japan), Sinocare (China), B. Braun Melsungen AG (Germany), and i-Sens, Inc., (South Korea), etc.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

North America

U.S.
Rest of N.A.

Europe

Germany
Italy
France
Rest of E.U.

Asia-Pacific

Japan
China
India
Rest of APAC

Rest of the World (RoW)

Brazil
Rest of Latin America
The Middle East & Others

1 EXECUTIVE SUMMARY
2 INTRODUCTION

2.1 KEY TAKEAWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY

2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS

3 MARKET ANALYSIS

3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET

3.3.1 DRIVERS AND OPPORTUNITIES

3.3.1.1 THE GLOBAL RISE IN THE PREVALENCE AND INCIDENCE OF DIABETES
3.3.1.2 INCREASING DEMAND FOR MINIMALLY OR NON-INVASIVE AND POINT-OF-CARE DEVICES.
3.3.1.3 INCREASING R & D INVESTMENTS
3.3.1.4 GROWING DIFFUSION OF SMART DEVICES AND DIGITAL PLATFORMS INCREASING COMPLIANCE AND MANAGEMENT OF DIABETES

3.3.2 RESTRAINTS AND THREATS

3.3.2.1 HIGH COST ASSOCIATED WITH THE PRODUCTS
3.3.2.2 INADEQUATE REIMBURSEMENT
3.3.2.3 PRODUCT RECALLS
3.3.2.4 STRICT REGULATION OF GLUCOSE MONITORING DEVICES BY REGULATORY ORGANIZATIONS LIKE THE FDA AND OTHERS
3.3.2.5 PRIVACY CONCERN AND SAFETY ISSUES IN CONNECTED DEVICES

3.4 REGULATORY AFFAIRS

3.4.1 U.S.
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 INDIA
3.4.5 JAPAN

3.5 REIMBURSEMENT SCENARIO
3.6 PATENT ANALYSIS
3.7 TECHNOLOGY ADVANCEMENTS

3.7.1 WIRELESS SMART CONTACT LENS
3.7.2 SALIVA BASED BIOSENSORS
3.7.3 RF (RADIOFREQENCY) SENSOR FOR CGM

3.8 PRODUCT LAUNCHES AND APPROVALS
3.9 FUNDING SCENARIO
3.10 PORTER’S FIVE FORCE ANALYSIS

3.10.1 THREAT OF NEW ENTRANTS
3.10.2 THREAT OF SUBSTITUTES
3.10.3 BARGAINING POWER OF SUPPLIERS
3.10.4 BARGAINING POWER OF BUYERS
3.10.5 RIVALRY AMONG EXISTING COMPETITORS

3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS

3.11.1 GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
3.11.2 SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS
3.11.3 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS

3.12 REGIONAL MARKET SHARE ANALYSIS

3.12.1 NORTH AMERICA SELF MONITORING OF BLOOD GLUCOSE MARKET SHARE ANALSIS
3.12.2 EUROPE SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.12.3 ASIA-PACIFIC SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.12.4 ROW SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.12.5 NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.12.6 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.12.7 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS
3.12.8 ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS

3.13 UNITS SOLD

3.13.1 GLUCOSE TESTING STRIPS UNITS SOLD
3.13.2 NUMBER OF CGM SENSORS SOLD

3.14 MARKET PENETRATION ANALYSIS
3.15 COVID-19 IMPACT

3.15.1 COVID-19 IMPACT ON GLUCOSE MONITORING MARKET
3.15.2 COVID IMPACT ON ELECTIVE SURGICAL PROCEDURES
3.15.3 COVID IMPACT ON SUPPLY CHAIN
3.15.4 COVID IMPACT ON CONSUMERS

4 GLUCOSE MONITORING GLOBAL MARKET, BY PRODUCTS

4.1 INTRODUCTION
4.2 INVASIVE GLUCOSE MONITORING

4.2.1 SELF GLUCOSE MONITORING

4.2.1.1 BLOOD GLUCOSE METER
4.2.1.2 BLOOD GLUCOSE TESTING STRIPS
4.2.1.3 LANCETS
4.2.1.4 OTHERS

4.2.2 CONTINUOUS GLUCOSE MONITORING

4.2.2.1 GLUCOSE SENSORS
4.2.2.2 TRANSMITTERS AND RECEIVERS

4.3 NON-INVASIVE GLUCOSE MONITORING
4.4 LAB BASED GLUCOSE MONITORING

5 GLUCOSE MONITORING GLOBAL MARKET, BY SAMPLE SOURCE

5.1 INTRODUCTION
5.2 BLOOD-BASED GLUCOSE MONITORING
5.3 URINE BASED GLUCOSE MONITORING
5.4 OTHER SOURCES BASED GLUCOSE MONITORING

6 GLUCOSE MONITORING GLOBAL MARKET, BY END-USERS

6.1 INTRODUCTION
6.2 HOSPITALS
6.3 HOME CARE
6.4 PRIVATE CLINICS
6.5 AMBULATORY SETTINGS

7 REGIONAL ANALYSIS

7.1 INTRODUCTION
7.2 NORTH AMERICA

7.2.1 U.S.
7.2.2 REST OF NORTH AMERICA

7.3 EUROPE

7.3.1 GERMANY
7.3.2 ITALY
7.3.3 FRANCE
7.3.4 REST OF EUROPE

7.4 ASIA - PACIFIC

7.4.1 JAPAN
7.4.2 CHINA
7.4.3 INDIA
7.4.4 REST OF ASIA-PACIFIC

7.5 REST OF THE WORLD

7.5.1 BRAZIL
7.5.2 MIDDLE EAST & OTHERS
7.5.3 REST OF LATIN AMERICA

8 COMPETITIVE LANDSCAPE

8.1 INTRODUCTION
8.2 APPROVAL
8.3 AGREEMENTS, COLLABORATION & PARTNERSHIPS
8.4 NEW PRODUCT LAUNCH
8.5 ACQUISITION
8.6 FUNDING
8.7 OTHER DEVELOPMENTS

9 MAJOR COMPANIES

9.1 ABBOTT LABORATORIES, INC

9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGY
9.1.6 SWOT ANALYSIS

9.2 ARKRAY, INC.

9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS

9.3 B.BRAUN MELSUNGEN AG

9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS

9.4 DEXCOM, INC.

9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS

9.5 I-SENS, INC.

9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 KEY DEVELOPMENTS
9.5.5 BUSINESS STRATEGY
9.5.6 SWOT ANALYSIS

9.6 LIFESCAN

9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS STRATEGY
9.6.6 SWOT ANALYSIS

9.7 MEDTRONIC, PLC

9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS STRATEGY
9.7.6 SWOT ANALYSIS

9.8 PHC HOLDINGS (ASCENCIA DIABETES)

9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS STRATEGY
9.8.6 SWOT ANALYSIS

9.9 ROCHE HOLDINGS AG

9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGY
9.9.6 SWOT ANALYSIS

9.10 SINOCARE INC.

9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS

LIST OF TABLES

TABLE 1 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
TABLE 2 SELF-MONITORING GLUCOSE TESTING STRIPS GLOBAL UNITS SOLD, BY REGION, (2019-2027) (MN)
TABLE 3 CGM SENSORS GLOBAL UNITS SOLD, BY REGION, (2019-2027) (MN)
TABLE 4 GLUCOSE MONITORING DEVICES GLOBAL MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
TABLE 5 INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 6 INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
TABLE 7 SELF-MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
TABLE 8 SELF MONITORING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 9 BLOOD GLUCOSE METER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 10 BLOOD GLUCOSE TESTING STRIPS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 11 LANCETS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 12 OTHERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 13 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 14 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS, (2020-2027) ($MN)
TABLE 15 GLUCOSE SENSORS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 16 TRANSMITTER AND RECEIVER GLOBAL MARKET REVENUE, BY REGION, (2020-2027) ($MN)
TABLE 17 NON-INVASIVE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 18 LAB BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 19 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY SAMPLE SOURCE, (2019-2027) ($MN)
TABLE 20 BLOOD-BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 21 URINE BASED GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 22 OTHER SOURCES BASED GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 23 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY END USER, (2019-2027) ($MN)
TABLE 24 HOSPITAL GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 25 HOME CARE GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 26 PRIVATE CLINICS GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 27 AMBULATORY SETTING GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 28 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
TABLE 29 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 30 NORTH AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 31 NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 32 NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 33 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2019-2027) ($MN)
TABLE 34 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2019-2027) ($MN)
TABLE 35 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2019-2027) ($MN)
TABLE 36 U.S. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 37 REST OF N. A. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 38 EUROPE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 39 EUROPE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 40 EUROPE SELF BLOOD GLUCOSE MONITORING DEVICES MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 41 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 42 EUROPE GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2019-2027) ($MN)
TABLE 43 EUROPE GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2019-2027) ($MN)
TABLE 44 EUROPE GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2019-2027) ($MN)
TABLE 45 GERMANY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 46 ITALY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 47 FRANCE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 48 REST OF E.U. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 49 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 50 ASIA-PACIFIC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 51 ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 52 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 53 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2019-2027) ($MN)
TABLE 54 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2019-2027) ($MN)
TABLE 55 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2019-2027) ($MN)
TABLE 56 JAPAN INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 57 CHINA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 58 INDIA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 59 REST OF APAC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 60 ROW GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 61 ROW INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 62 ROW SELF BLOOD GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 63 ROW CONTINUOUS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 64 ROW GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2019-2027) ($MN)
TABLE 65 ROW GLUCOSE MONITORING MARKET REVENUE, BY END-USER (2019-2027) ($MN)
TABLE 66 ROW GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2019-2027) ($MN)
TABLE 67 BRAZIL INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 68 MIDDLE EAST & OTHERS INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 69 REST OF LATIN AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2019-2027) ($MN)
TABLE 70 NEW PRODUCT LAUNCHES (2020-2021)
TABLE 71 COLLABORATION & PARTNERSHIPS (2020-2021)
TABLE 72 NEW PRODUCT LAUNCH (2020-2021)
TABLE 73 ACQUISITION (2020-2021)
TABLE 74 ACQUISITION (2020-2021)
TABLE 75 OTHERS (2020-2021)
TABLE 76 ABBOTT LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 77 ABBOTT LABORATORIES, INC: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
TABLE 78 ABBOTT LABORATORIES, INC: TOTAL REVENUE OF MEDICAL DEVICES, BY SUB-SEGMENTS, (2018-2020) ($MN)
TABLE 79 ABBOTT LABORATORIES, INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 80 B.BRAUN MELSUNGEN: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
TABLE 81 B.BRAUN MELSUNGEN: TOTAL REVENUE, BY SEGMENTS (2018-2020) ($MN)
TABLE 82 B.BRAUN MELSUNGEN: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
TABLE 83 DEXCOM INC: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
TABLE 84 DEXCOM INC: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
TABLE 85 I-SENS, INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 86 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
TABLE 87 MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2019-2021) (Q3) ($MN)
TABLE 88 MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q3) ($MN)
TABLE 89 ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 90 ROCHE HOLDINGS AG: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
TABLE 91 ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE, BY TYPES, (2018-2020) ($MN)
TABLE 92 ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 93 SINOCARE, INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)

LIST OF FIGURES

FIGURE 1 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: GLUCOSE MONITORING GLOBAL MARKET
FIGURE 3 GLUCOSE MONITORING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 GLUCOSE MONITORING GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 GLUCOSE MONITORING GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 GLUCOSE MONITORING GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 GLUCOSE MONITORING GLOBAL MARKET: PATENT FILING, BY MAJOR PLAYERS (2016-2021)
FIGURE 9 GLUCOSE MONITORING MARKET: PORTER’S ANALYSIS
FIGURE 10 GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 11 SELF BLOOD GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 12 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 13 NORTH AMERICA SELF MONITORING OF BLOOD GLUCOSE MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 14 EUROPE SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 15 ASIA-PACIFIC SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 16 ROW SELF GLUCOSE MONITORING MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 17 NORTH AMERICA CONTINOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 18 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 19 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 20 ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020
FIGURE 21 SELF MONITORING GLUCOSE TEST STRIPS GLOBAL UNITS SOLD, BY REGION AND COUNTRYWISE (2020) (MN)
FIGURE 22 CGM SENSORS GLOBAL UNITS SOLD, BY REGION AND COUNTRYWISE (2020) (MN)
FIGURE 23 GLOBAL SMBG DEVICES PENETRATION, (2020)
FIGURE 24 GLOBAL CGM DEVICES PENETRATION, (2020)
FIGURE 25 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY PRODUCTS (2020) ($MN)
FIGURE 26 CONTINUOUS GLUCOSE MONITORING GLOBAL MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
FIGURE 27 NON-INVASIVE GLUCOSE MONITORS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 28 LAB BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 29 GLUCOSE MONITORING GLOBAL MARKET SHARE, BY SAMPLE SOURCE (2020 V/S 2027) (%)
FIGURE 30 URINE BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 31 OTHER SOURCES BASED GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 32 GLUCOSE MONITORING GLOBAL MARKET SHARE, BY END USER (2020) (%)
FIGURE 33 HOME CARE GLUCOSE MONITORING GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 34 GLUCOSE MONITORING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
FIGURE 35 NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020) ($MN)
FIGURE 36 NORTH AMERICA SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
FIGURE 37 NORTH AMERICA CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
FIGURE 38 NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BY SAMPLE SOURCE (2020 V/S 2027) (%)
FIGURE 39 NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
FIGURE 40 NORTH AMERICA GLUCOSE MONITORING MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 41 NORTH AMERICA SMBG MARKET PENETRATION, (2020)
FIGURE 42 NORTH AMERICA CGM MARKET PENETRATION, (2020)
FIGURE 43 U.S. GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE & BY END-USER (2020 V/S 2027)($MN)
FIGURE 44 U.S. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 45 U.S. SMBG MARKET PENETRATION, (2020)
FIGURE 46 U.S. CGM MARKET PENETRATION, (2020)
FIGURE 47 REST OF NORTH AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCT, BY SAMPLE SOURCE, AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 48 REST OF N. A. INVASIVEGLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 49 REST OF N.A. SMBG MARKET PENETRATION, (2020)
FIGURE 50 REST OF N.A. CGM MARKET PENETRATION, (2020)
FIGURE 51 EUROPE AND INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020) ($MN)
FIGURE 52 EUROPE SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
FIGURE 53 EUROPE CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
FIGURE 54 EUROPE GLUCOSE MONITORING MARKET SHARE, BY SAMPLE SOURCE (2020 V/S 2027) (%)
FIGURE 55 EUROPE GLUCOSE MONITORING MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
FIGURE 56 EUROPE GLUCOSE MONITORING MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 57 EUROPE SMBG MARKET PENETRATION, (2020)
FIGURE 58 EUROPE CGM MARKET PENETRATION, (2020)
FIGURE 59 GERMANY GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE & BY END-USER (2020 V/S 2027) ($MN)
FIGURE 60 GERMANY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 61 GERMANY SMBG MARKET PENETRATION, (2020)
FIGURE 62 GERMANY CGM MARKET PENETRATION, (2020)
FIGURE 63 ITALY GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE & BY-END-USER (2020 V/S 2027) ($MN)
FIGURE 64 ITALY INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 65 ITALY SMBG MARKET PENETRATION, (2020)
FIGURE 66 ITALY CGM MARKET PENETRATION, (2020)
FIGURE 67 FRANCE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE, AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 68 FRANCE INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 69 FRANCE SMBG MARKET PENETRATION (2020)
FIGURE 70 FRANCE CGM MARKET PENETRATION (2020)
FIGURE 71 REST OF EUROPE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE, AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 72 REST OF E.U. INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 73 REST OF EUROPE SMBG MARKET PENETRATION (2020)
FIGURE 74 REST OF EUROPE CGM MARKET PENETRATION (2020)
FIGURE 75 ASIA-PACIFIC & INVASIVE GLUCOSE MONITORING DEVICES MARKET REVENUE, BY PRODUCTS (2020) ($MN)
FIGURE 76 ASIA-PACIFIC SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
FIGURE 77 ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
FIGURE 78 ASIA-PACIFIC GLUCOSE MONITORING MARKET REVENUE, BY SAMPLE SOURCE (2020 V/S 2027) ($MN)
FIGURE 79 ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
FIGURE 80 ASIA-PACIFIC GLUCOSE MONITORING MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 81 ASIA-PACIFIC SMBG MARKET PENETRATION (2020)
FIGURE 82 ASIA-PACIFIC CGM MARKET PENETRATION (2020)
FIGURE 83 JAPAN GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 84 JAPAN INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 85 JAPAN SMBG MARKET PENETRATION (2020)
FIGURE 86 JAPAN CGM MARKET PENETRATION (2020)
FIGURE 87 CHINA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 88 CHINA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 89 0 CHINA SMBG MARKET PENETRATION (2020)
FIGURE 90 CHINA CGM MARKET PENETRATION (2020)
FIGURE 91 INDIA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 92 INDIA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 93 INDIA SMBG MARKET PENETRATION (2020)
FIGURE 94 INDIA CGM MARKET PENETRATION (2020)
FIGURE 95 REST OF APAC GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 96 REST OF APAC INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 97 REST OF APAC SMBG MARKET PENETRATION (2020)
FIGURE 98 REST OF APAC CGM MARKET PENETRATION (2020)
FIGURE 99 ROW & INVASIVE GLUCOSE MONITORING DEVICES MARKET REVENUE, BY PRODUCTS (2020) ($MN)
FIGURE 100 ROW SELF BLOOD GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
FIGURE 101 ROW CONTINUOUS GLUCOSE MONITORING MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
FIGURE 102 ROW GLUCOSE MONITORING MARKET SHARE, BY SAMPLE SOURCE (2020 V/S 2027) (%)
FIGURE 103 ROW GLUCOSE MONITORING MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
FIGURE 104 ROW GLUCOSE MONITORING MARKET REVENUE, BY COUNTRY (2020 V/S 2027) ($MN)
FIGURE 105 ROW SMBG MARKET PENETRATION (2020)
FIGURE 106 ROW CGM MARKET PENETRATION (2020)
FIGURE 107 BRAZIL GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 108 BRAZIL INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 109 BRAZIL SMBG MARKET PENETRATION (2020)
FIGURE 110 BRAZIL CGM MARKET PENETRATION (2020)
FIGURE 111 MIDDLE EAST & OTHERS GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 112 MIDDLE EAST & OTHERS INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 113 MIDDLE EAST & OTHERS SMBG MARKET PENETRATION (2020)
FIGURE 114 MIDDLE EAST & OTHERS CGM MARKET PENETRATION (2020)
FIGURE 115 REST OF LATIN AMERICA GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS, BY SAMPLE SOURCE AND BY END-USER (2020 V/S 2027) ($MN)
FIGURE 116 REST OF LATIN AMERICA INVASIVE GLUCOSE MONITORING MARKET REVENUE, BY PRODUCTS (2020 V/S 2027) ($MN)
FIGURE 117 LATIN AMERICA SMBG MARKET PENETRATION (2020)
FIGURE 118 LATIN AMERICA CGM MARKET PENETRATION (2020)
FIGURE 119 KEY GROWTH STRATEGIES (2020–2021)
FIGURE 120 SWOT: ABBOTT LABORATORIES
FIGURE 121 SWOT: ARKRAY, INC
FIGURE 122 SWOT: B BRAUN MELSUNGEN
FIGURE 123 SWOT: DEXCOM INC.
FIGURE 124 SWOT: I-SENS, INC.
FIGURE 125 SWOT: LIFESCAN
FIGURE 126 SWOT: MEDTRONIC, PLC
FIGURE 127 SWOT: PHC HOLDINGS (ASCENSIA DIABETES CARE)
FIGURE 128 SWOT: ROCHE HOLDINGS AG
FIGURE 129 SWOT: SINOCARE

LIST OF COMPANIES MENTIONED IN THE REPORT

1 77 ELEKTRONIKA KFT
2 A&T CORPORATION
3 ABBOTT LABORATORIES
4 ACON DIABETES CARE INTERNATIONAL
5 ADALTIS S.R.L
6 AGAMATRIX, INC.
7 ALLIANCE INTERNATIONAL CO. LTD
8 ALLMEDICUS CO., LTD
9 AMBROSIA SYSTEMS, INC
10 ANDON HEALTH CO., LTD.
11 APEX BIOTECHNOLOGY CORP.
12 ARKRAY, INC.
13 B. BRAUN MELSUNGEN AG
14 BEATO CURV
15 BECTON DICKINSON AND COMPANY
16 BEIJING YICHENG BIOELECTRONICS TECHNOLOGY CO., LTD.
17 BEURER GMBH
18 BIOCHEMICAL SYSTEMS INTERNATIONAL S.P.A.
19 BIOLAND TECHNOLOGY LTD.
20 BIONIME CORPORATION
21 BIOPTIK LTD.
22 BIO-RAD LABORATORIES, INC
23 BIOTEST MEDICAL CORPORATION
24 BREMED LIMITED
25 CAMBRIDGE SENSORS LTD (MICRODOT)
26 CHUNGDO PHARM. CO., LTD
27 CONTEC MEDICAL SYSTEMS CO., LTD.
28 CONVERGENT TECHNOLOGIES GMBH & CO. KG
29 CTK BIOTECH, INC
30 DANAHER CORPORATION(HEMOCUE)
31 DARIO HEALTH CORP.
32 DELBIO, INC.
33 DEXCOM, INC
34 DIABETOMICS, INC
35 DIAMONTECH AG
36 DR. MOREPEN
37 EKF DIAGNOSTICS
38 EPS BIO TECHNOLOGY CORP.
39 EVIA MEDICAL TECHNOLOGIES
40 FIA BIOMED GMBH
41 FORA CARE, INC
42 GENERAL LIFE BIOTECHNOLOGY CO., LTD.
43 GENESIS HEALTH TECHNOLOGIES, INC.
44 GLUCORX
45 GLUCOSTRATUS LTD
46 GLYSENS INCORPORATED
47 HAIDEN TECHNOLOGY PVT. LTD
48 HANGZHOU SEJOY ELECTRONICS & INSTRUMENTS CO., LTD.
49 HMD BIOMEDICAL
50 HUBDIC CO LTD
51 IHEALTH LABS, INC.
52 IME-DC GMBH
53 IN4 TECHNOLOGY CORPORATION
54 INTEGRITY APPLICATIONS
55 INTUITY MEDICAL, INC.
56 I-SENS
57 IXENSOR COMPANY LTD.
58 JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD (YUWELL)
59 K-JUMP HEALTH CO., LTD.
60 LIFOTRONIC TECHNOLOGY CO., LTD
61 LOBECK MEDICAL AG
62 L-TAC MEDICARE PTE LTD.
63 MEDISANA, GMBH
64 MEDIWISE (V.S. INTERNATIONAL)
65 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
66 MEDTRONIC, PLC
67 MEDTRUM TECHNOLOGIES, INC
68 MENARINI GROUP (A. MENARINI DIAGNOSTICS S.R.L)
69 MICO BIOMED CO., LTD.
70 MICROTECH MEDICAL, INC. (AIDEX, LTD)
71 NATIONAL DIAGNOSTIC PRODUCTS PTY LTD
72 NEMAURA MEDICAL,INC.
73 NIPRO CORPORATION
74 NOVA BIOMEDICAL
75 NOVIOSENSE BV
76 OK BIOTECH CO., LTD
77 OMRON HEALTHCARE
78 OSANG HEALTH CARE CO LTD
79 PALMDOC, LTD
80 PEPEX BIOMEDICAL
81 PHARMA TECH SOLUTIONS, INC.
82 PHC HOLDINGS (ASCENSIA DIABETES CARE HOLDINGS AG)
83 PHILIPS (BIOTELEMETRY, INC)
84 PHILOSYS CO., LTD.
85 PKVITALITY
86 PLATINUM EQUITY (LIFE SCAN, INC.)
87 PRODIGY DIABETES CARE, LLC
88 PULSATOM HEALTHCARE PRIVATE LIMITED
89 ROCHE DIAGNOSTICS
90 ROMED HOLLAND (VAN OOSTVEEN MEDICAL B.V.)
91 SANOFI
92 SD BIOSENSOR, INC.
93 SENSEONICS, INC.
94 SHENZHEN ESER INDUSTRIAL DESIGN LTD. CO.
95 SINOCARE
96 TAIDOC TECHNOLOGY CORPORATION
97 TERUMO
98 THERMO FISHER SCIENTIFIC
99 TIANJIN EMPECS MEDICAL DEVICE CO., LTD.
100 TRINITY BIOTECH, PLC
101 TRULY INSTRUMENT LIMITED
102 TYSON BIORESEARCH INC
103 VISGENEER INC
104 VITREX MEDICAL A/S
105 VIVACHEK LABORATORIES, INC.
106 WOCKHARDT LIMITED
107 YPSOMED AG

Glucose Monitoring Global Market – Forecast To 2027

LIST OF TABLES

LIST OF FIGURES

LIST OF COMPANIES MENTIONED IN THE REPORT

IQ4I HEALTHCARE REPORTS

about IQ4I

Get in Touch

IQ4I Quality Accredit Certificate

Subscribe to Newsletter

Medical Devices

Glucose Monitoring Global Market – Forecast To 2027

Glucose Monitoring Global Market – Forecast To 2027

LIST OF TABLES

LIST OF FIGURES

LIST OF COMPANIES MENTIONED IN THE REPORT

IQ4I HEALTHCARE REPORTS